FDA Grants Interchangeability for Celltrion’s Denosumab Biosimilars
Incheon, South Korea, October 30, 2025 — Celltrion, Inc., a global biopharmaceutical company specializing in biosimilars and innovative biologics,...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Incheon, South Korea, October 30, 2025 — Celltrion, Inc., a global biopharmaceutical company specializing in biosimilars and innovative biologics,...
Incheon, South Korea – October 16, 2025 – CelltrionUSA, a subsidiary of Celltrion Inc., announced that the U.S. Food...
INCHEON, South Korea, Oct. 9, 2025 — Celltrion, Inc., a global biopharmaceutical innovator, announced that the U.S. Food and...
